Global 신약개발! 메지온이 그 꿈을 실현합니다.
Location: South Korea, Seoul
Investors 1
| Date | Name | Website |
| - | E&Inve... | eninvestme... |
Mentions in press and media 3
| Date | Title | Description |
| 02.03.2024 | Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2 | FORT LEE, N.J., March 2, 2024 /PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or... |
| 21.12.2021 | Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting | SEOUL, South Korea and BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (Mezzion Pharma) announces that new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial... |
| 15.06.2021 | Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations | SEOUL, Republic of Korea, June 15, 2021 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (140410.KQ), and Mezzion Pharmaceuticals, Inc. (individually or collectively, "Mezzion"), a leader in the field of rare single ventricle congenital h... |